Targeting Specific Protein Fragments May Be Key to Treating Huntington’s Disease According to New Mouse Study

UW Medicine study reveals that targeting the huntingtin 1a fragment is more effective than whole-protein suppression for treating Huntington’s disease.

By: AXL Media

Published: Mar 18, 2026, 2:31 PM EDT

Source: Information for this report was sourced from University of Washington School of Medicine

A Shift in Strategy for Inherited Neurodegenerative Disorders

New research led by the University of Washington School of Medicine indicates that current experimental therapies for Huntington’s disease may need a strategic pivot to achieve clinical success. The study, published in Science Translational Medicine, suggests that targeting a specific fragment of the mutant protein is significantly more effective than aiming at the protein in its entirety. While several treatments currently in human trials focus on reducing the overall production of the abnormal huntingtin protein, this new data from animal models implies that these efforts may fail if a toxic segment known as huntingtin 1a remains active within the brain.

The Pathological Impact of the Huntingtin Mutation

Huntington’s disease is a fatal inherited condition triggered by a mutation in the huntingtin gene, which leads to the accumulation of abnormal proteins in brain cells. These proteins interfere with vital cellular functions and eventually form large, visible aggregates that result in widespread cell death. Patients typically experience an onset of symptoms in their 40s, beginning with involuntary movements and balance issues, eventually progressing to a total loss of speech, mobility, and cognitive function. Senior author Jeffrey Carroll notes that while the science behind these findings is solid, it suggests that current pharmaceutical designs may be overlooking a critical driver of the disease's progression.

Utilizing Antisense Oligonucleotides for Protein Suppression

The most promising modern therapies utilize antisense oligonucleotides, which are short sequences of DNA designed to sabotage the translation of genetic instructions into harmful proteins. By binding to messenger RNA, these treatments trigger cellular enzymes to cut the strand, preventing the assembly of the complete mutant protein. In this study, researchers compared different versions of these treatments to see which moved the needle on disease markers. They discovered that the most successful intervention was one that bound very near the beginning of the RNA strand, effectively suppressing both the full-length protein and the elusive huntingtin 1a fragment.